Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 11/20 | 0.55 |
| ▸ | REN | P00797 | 3/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30440351 | 0.97 | CMA1 (0.55) | CMA1RENF2PRSS1ITGB3 | |
| SCHEMBL30439967 | 0.94 | CMA1 (0.55) | CMA1RENF2PRSS1ITGB3 | |
| SCHEMBL24372015 | 0.89 | CMA1 (0.51) | CMA1RENF2PRSS1ITGB3 | |
| SCHEMBL13323714 | 0.89 | CMA1 (0.51) | CMA1RENF2PRSS1ITGB3 | |
| SCHEMBL22127929 | 0.89 | CMA1 (0.52) | CMA1RENF2PRSS1ITGB3 | |
| SCHEMBL22127777 | 0.89 | CMA1 (0.52) | CMA1RENF2PRSS1ITGB3 | |
| SCHEMBL22127925 | 0.89 | CMA1 (0.52) | CMA1RENF2PRSS1ITGB3 | |
| SCHEMBL22127775 | 0.89 | CMA1 (0.52) | CMA1RENF2PRSS1ITGB3 | |
| SCHEMBL13323704 | 0.89 | CMA1 (0.52) | CMA1RENF2PRSS1ITGB3 | |
| SCHEMBL22127779 | 0.89 | CMA1 (0.52) | CMA1RENF2PRSS1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9220711-B2 | Compounds for the treatment of pathologies associated with aging and degenerative disorders | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2015-12-29 | — | — | US | disclosed |
| US-8937086-B2 | Compounds for the treatment of pathologies associated with aging and degenerative disorders | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2015-01-20 | — | — | US | disclosed |
| US-20120004263-A1 | Compounds for the treatment of pathologies associated with aging and degenerative disorders | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004263-A1 | Compounds for the treatment of pathologies associated with aging and degenerative disorders | GLA, AGER, SIRT1 | CMA1 2380/4885REN 1398/4885F2 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.